Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_734_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
51 Мб
Скачать
10 Total Pancreatectomy withIslet Cell Autotransplantation
161

Procedural Aspects

Preoperative Care
Prophylactic perioperative antibiotics according to local protocol are administered.
Total Pancreatectomy
There are several surgical variations to the total pancreatectomy and biliary and gastrointestinal reconstruction.
Removal of the pancreas as a single specimen vs. two sections is dependent on institutional preference, degree of pancreatic inammation and brosis, and prior decompression or resection procedures.
Splenic preservation is of interest, yet associated splenic vein thrombosis, densely adherent splenic vessels in advanced forms of chronic pancreatitis, and the critical need to avoid prolonged warm ischemia time, limits most attempts at splenic preservation. In our institution, about 70% undergo splenectomy [16], but in one of the largest multicenter TPIAT consortiums (Prospective Observational Study of TPIAT, POST), 95% of adult and 100% of children have undergone splenec­tomy [10].
Our institution does not preserve the pylorus. Our research has demonstrated that the pylorus preserving technique has a higher rate of long-term complications, up to 55% compared to 15% of the classic technique, particularly due to marginal ulcer­ation [16]. It is also of importance to preserve the coronary vein, which will remain as the only venous drainage of the stomach, and its sacrice could lead to venous congestion, gastric ischemia, or delayed gastric emptying.
It is imperative to limit warm ischemia time, with ligation of the vascular ow of the pancreas only after complete mobilization and preparation for removal. Precise hemostasis in anticipation for full heparinization at the time of islet cell infusion must also be performed. The gastroduodenal artery (GDA) is test-clamped to con­rm preservation of ow to the hepatic proper artery and is only ligated immedi­ately prior to nal dissection of the uncinate process and specimen removal.
Various approaches to gastrointestinal and biliary reconstruction have been described. At our institution, the jejunum is brought behind the mesenteric vessels through the aortomesenteric window to lie in the position of the native duodenum and an end-to-side hepaticojejunostomy with interrupted 4–0 polydioxanone suture (PDS) is created. An antecolic end-to-side loop gastrojejunostomy is then created with an inner layer of running 3–0 PDS and outer layer of 3–0 silk.
162
J. Chang et al.
After completion of the gastrointestinal reconstruction, the fascia and skin are closed, and the patient is taken to the post-anesthesia care unit (PACU) intubated on a continuous insulin infusion for a planned reopening of recent laparotomy and islet infusion once islet cell isolation and purication is completed.
Islet Cell Isolation, Purication
Our institution successfully performs islet cell isolation with remote processing at a location 2h drive time away. Once the pancreas is removed, the surgeon ushes the organ via the splenic artery and GDA with the University of Wisconsin or histidine­tryptophan-ketoglutarate (HTK) solution, both of which are commonly used for solid organ perseveration, for cold preservation prior to transportation. We believe that lack of onsite or local islet-processing facility should not be a barrier to TPIAT and have comparable outcomes in terms of islet yield and postoperative insulin independence [17]. There is an 8–10h total time lapse between complete removal of specimen and islet infusion at our institution. Other institutions have reported up to 48h intervals between specimen removal and islet infusion.
The pancreas undergoes enzymatic with collagenase and proteinase and mechan­ical digestion via the Ricordi digestion isolation changer to yield islet isolates [18]. To initiate tissue digestion and dissolution, collagenase and proteinase are infused under pressure into the main pancreatic duct to distend the intact gland. After dis­ruption, the pancreas is sectioned and placed in a Ricordi digestion isolation cham­ber for gentle mechanical dispersion until the islets are separated from acinar tissue as detected by microscopic analysis with dithizone staining. The extent of islet puri­cation is imprecise as a balance must be achieved between purifying the islets away from surrounding tissue (to reduce the volume of the infusate and minimize thrombogenic particulate matter) while preserving the absolute number of islets with each successive purication cycle. Purication is achieved through continuous density gradient centrifugation. Final islet counts can be determined using an auto­mated islet counter or standard manual counting methods, commonly reported as a standardized islet equivalent and islet equivalent per kilogram of body weight. One islet equivalent is equal to the volume of an islet with a diameter of 150μm. Mean islet yield from large case series are listed in Table 10.2. Before transplant, islet preparations are suspended in a 50:50 solution of 20% human serum albumin and transplant media with antibiotics solution, such as ciprooxacin. Although there is bacterial contamination from the attached duodenum, there is no clinical benet to routinely culture this islet preparation. In our retrospective analysis, up to 65% of patients will have positive intraoperative cultures with no difference in infectious complication rate [19].
10 Total Pancreatectomy withIslet Cell Autotransplantation
Islet Infusion
163
In our institution, a re-exploratory laparotomy is performed to conrm hemostasis and examine the biliary and gastrointestinal reconstruction. The portal system can be accessed through the catheterization of the splenic vein, mesenteric vein, umbili­cal vein in the falciform ligament, or transhepatic direct portal puncture. Our institu­tion typically accesses the splenic vein remnant with a 10-gauge angiocatheter secured with a suture. If the splenic vein remnant is not appropriate, a mesenteric vein such as the inferior mesenteric vein is used. The superior mesenteric vein is a less preferred option as it requires oversewing of the site of venipuncture with 5–0 permanent monolament suture. A transjugular intrahepatic portosystemic shunt (TIPS) performed by interventional radiology has also demonstrated to be a viable option while preserving portal vein pressure in our limited experience with liver transplant patients. Other institutions have also reported portal vein infusion via percutaneous transhepatic cannulation of the portal system, avoiding the need for a relaparotomy. The absolute volume of islets that can be delivered via intraportal infusion is dependent on the size of the liver and the degree of steatosis. Portal vein pressures are checked periodically with a manometer and if it reaches 25cm H
2
O, the infusion is stopped, and the remaining islets are placed in the peritoneal cavity. The major complications of portal access are portal hypertension and portal vein thrombosis. Weight-based systemic therapeutic heparinization with an initial bolus dosage of 60–70units per kg is initiated immediately prior to islet infusion. Our
164
J. Chang et al.
research has demonstrated that there are no statistically signicant differences in postoperative hemorrhage rates when compared by rates of lower (<60units per kg) and higher (60units per kg) rates of heparin dosing [19]. Prophylactic anticoagu­lation is continued postoperatively to help prevent portal vein thrombosis and plate­let aggregation. Other current methods to reduce these complications include limiting the volume and rate of infusion and administering dextran for 48h after surgery to decrease the inammatory reaction in children [20].
Minimally Invasive Surgery (MIS)
The case complexity and need to minimize warm ischemia time has limited mini­mally invasive techniques for TPIAT.Publications on all the components of TPIAT (total pancreatectomy, gastrointestinal reconstruction, and AIT) are restricted to limited case series.
At Johns Hopkins University, about 60% of TPIAT operations are performed laparoscopically or laparoscopically assisted with an operative room equipped with an islet isolation laboratory for immediate processing [21]. They sequentially resect the pancreas into two stages—rst the head and then the body and tail, which is extracted via the periumbilical 12mm port. The hepaticojejunostomy is performed using a single layer of running 4–0 barbed sutures [22]. The gastrojejunal anasto­mosis is performed antecolic, retrogastric along the posterior wall of the stomach with a laparoscopic stapler in a side-to-side technique. Occasionally, a Braun jeju­nojejunostomy will be created to reduce bile reux.
Once islet cells are ready for autotransplantation into the liver, a 15-gauge needle placed through a port site is guided into the portal vein. Once completed, the needle is removed, and direct pressure is applied to the site of the portal vein for hemostasis.
Most published literature regarding robot-assisted TPIAT are limited case reports [23]. There is one published series on robot-assisted TPIAT from the University of Arizona with six patients. Their technique is summarized below [24]. The University of Pittsburgh has published a successful case series on the robotic total pancreatec­tomy, including one case with TPIAT [25]. In the most recent ongoing POST con­sortium, 7% of adult TPIAT are performed robot-assisted, although their full data is yet to be published [10].
In the University of Arizona group, the pancreatic dissection is started from dis­tal pancreas towards the head, dividing the splenic artery and vein distal to the pancreatic tail to aid the dissection of the body and the tail off the retroperitoneum, then dissection of the superior mesenteric vein, portal vein, and splenic vein conu­ence. A Kocher maneuver is then performed to mobilize and subsequently divide the duodenum and the pancreatic head, which is removed en-bloc via a Pfannenstiel incision. The hepaticojejunostomy is created over a 5 French stent with running 4–0
10 Total Pancreatectomy withIslet Cell Autotransplantation
165
PDS sutures and the duodenojejunostomy is created with running 3–0 absorbable barbed sutures for the internal layer and running 3–0 nonabsorbable barbed sutures for the external layer. A stapled Braun jejunojejunostomy is created. A 14-gauge laparoscopic needle is inserted into the splenic vein (SV) stump. After completion of the infusion, the SV stump is double clipped.
There is institutional variation in the methods of islet infusion. Some centers may choose to use the inferior mesenteric vein or another colic vein branch; others have described performance of the islet infusion on the following day utilizing a tran­sjugular approach into the hepatic veins or a percutaneous transhepatic portal vein infusion with the assistance of interventional radiology.

Postoperative Care

Patients are transferred to the intensive care unit (ICU) after surgery with a continu­ous insulin infusion, extubated the next morning, and subsequently transferred out of the ICU within 24h on a standardized sliding scale algorithm with assistance from the endocrinology service. They are discharged on a basal bolus regimen to decrease the metabolic burden on the transplanted islets and allow for proper engraftment and revascularization.
All patients at our institution have a 10 French bridled nasojejunal feeding tube placed intraoperatively and are started on enteral feeds on postoperative day 1, which are continued until the patient demonstrates adequate oral intake.
Patients are also continued on deep vein thrombosis (DVT) prophylaxis while inpatient and discharged home on aspirin depending on the level of thrombocytosis from the splenectomy. Proton pump inhibitors are prescribed upon discharge for at least 3months to prevent marginal ulceration and metoclopramide for 2weeks to promote gastric motility. A taper to insulin independence is initiated in the outpa­tient setting with endocrinology.
The median postoperative length of stay is reported to be around 9–11days for adults and 15days for children [10, 16].
Lifelong pancreatic enzyme supplementation is required and annual nutritional monitoring for steatorrhea, body composition, and fat-soluble vitamins (A, D, and E), along with bone density is recommended.
Patients continue frequent follow-up with their endocrinologist for the rst year after TPIAT, with eventual transition to annual testing for diabetes which includes fasting plasma glucose, hemoglobin A1C, and c-peptide levels. These variables combined with ongoing insulin requirements compromise of the BETA-2 Score which could be used to assess graft function [26].
166
J. Chang et al.

Outcomes

Perioperative Data
Operative variables of mean operative time, estimated blood loss, and length of stay are listed in Table 10.1 comparing select studies on the open, laparoscopic, and robotic approach.
Perioperative Complications
TPIAT has one of the highest intrinsic complication rates of any elective operation. Immediate operative mortality has been reported to be 0–6% [11, 18]. Morbidity up to 50% has been described, with most commonly reported complications to be pneumonia, delayed gastric emptying, deep venous thrombosis, bleeding, and wound infection [16, 18, 19]. Thirty-day readmission rates range up to 25%, with the most common reason being surgical site infection and gastrointestinal issues (such as small bowel obstruction and delayed gastric emptying) [19]. Up to a 10% reoperative rate within 30days of TPIAT has been reported, most commonly for bleeding [10]. Despite the risks of hemorrhage associated with this procedure, there is a complex coagulation and pro-inammatory interface which increases thrombo­sis risk in these patients, due to the known smoldering inammatory state that increases venous thromboembolism risk in chronic pancreatitis patients [29], major operation with risk of signicant blood loss, and the instant blood-mediated inam­matory reaction with direct exposure of islets to plasma [20]. A complication spe­cic to this procedure is portal vein thrombosis (PVT), which has been described in up to 10% in adults [10]. Some institutions such as the University of Minnesota routinely screen their patients for PVT with ultrasound within the rst week of transplant [30], while ours does not.
Table 10.1 Perioperative data
Open Laparoscopic Robotic
Study sample size 112 195 20 6 Mean operative time
(min) Mean estimated blood
loss (mL) Mean length of stay
(days) Citation (year) Wilson (2014)
544 240 493 717
548.8 589 627.5 630
14 9 11 12.6
[27]
Morgan (2018) [15]
Fan (2017) [28]
Galvani (2014) [24]
10 Total Pancreatectomy withIslet Cell Autotransplantation
167
Endocrine Function
Most series report insulin independence in 20–40% of patients at 1–3years with manageable insulin requirements for the remainder of patients [7, 11, 31, 32]. These results are summarized in Table10.2. The number of islet equivalent per kilogram transplanted is the strongest predictor for insulin independence [31, 33, 34]. The incidence between obesity and insulin resistance is a known correlation, and it has been demonstrated that an absolute weight of 78kg or a BMI greater than 28 may have an increased chance of requiring long-term insulin supplementation in TPIAT patients [31].
Unfortunately, the function of transplanted islet grafts will decline over time. This decrease in function is partially attributed to the proven immediate inamma­tory response, termed instant blood-mediated inammatory reaction, when islets are exposed to blood, along with islet hypoxia which leads to islet apoptosis [20,
35]. Research into alternative low inammatory reaction transplant sites such as the
omentum, muscle, and bone marrow as well as adjuvant agents such as tumor necro­sis factor (TNF) blockers are ongoing [36].
Pain andQuality ofLife
Multiple studies have demonstrated the reduction of pain in these patients. About 50% of patients are able to be independent from opioids 1year after surgery, sum­marized in Table10.3 below [7, 27, 33, 34]. Pain, per patient reported outcomes, persists or recurs in about 10–20% of patients after TPIAT [5, 37].
Overall, patients report improvements in their perceived physical and mental health, as measured by patient reported outcome surveys, with some institutions reporting up to 92% of patients reporting an overall improvement in health [15, 27,
34], and 60–70% improvement in depression and anxiety although improvement in
Table 10.2 Islet yield and glucose control following TPIAT
Center
Study sample size 215 112 195 75 Mean age (years) 35.7 37.3 40.3 13.8 Mean islet yield
(IEG/kg) Insulin independence
1year after TPIAT Insulin independence
5years after TPIAT Citation (year) Bellin (2019)
University of Minnesota
3488 6027 3253 N/a
27.0% 38% 29% 37%
22.3% 27% 23% N/a
[34]
University of Cincinnati
Wilson (2014) [27]
Medical University of South Carolina
Morgan (2018) [15]
University of Minnesota
Chinnakotla (2014) [7]
168
Table 10.3 Pain control following TPIAT
Center
Study sample size 215 112 195 Preoperative mean oral
morphine equivalents (MEQ/d)
Mean oral morphine equivalents 1year after TPAIT (MEQ/d)
Narcotic independence 1year after TPIAT
Narcotic independence 5year after TPIAT
Citation (year) Bellin (2019)
University of Minnesota
N/a 118.9 208
N/a 74.1 60
46% 55% N/a
63% 73% N/a
[34]
University of Cincinnati
Wilson (2014) [27]
Medical University of South Carolina
Morgan (2018) [15]
J. Chang et al.
quality of life is not always associated with decreased opioid use [37]. The need to start insulin also has not been associated with a lower quality of life [38]. However, to provide consistency in reporting this data varies, and to address these critical research gaps, a multicenter research consortium called POST was started on 2017 to prospectively collect data about pain, quality of life, glycemic control, and cost­effectiveness in patients undergoing TPIAT [10].

References

1. Schnelldorfer T, Adams DB, Warshaw AL, Lillemoe KD, Sarr MG. Forgotten pioneers of pancreatic surgery: beyond the favorite few. Ann Surg. 2008;247(1):191–202.
2. van Heerden JA.The rst total pancreatectomy. Am J Surg. 1986;151(2):197–9.
3. Jahansouz C, Jahansouz C, Kumer SC, Brayman KL.Evolution of β-cell replacement therapy in diabetes mellitus: islet cell transplantation. J Transp Secur. 2011;2011:247959.
4. Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, etal. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg. 1980;192(4):526–42.
5. Bellin MD, Freeman ML, Gelrud A, Slivka A, Clavel A, Humar A, etal. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology. 2014;14(1):27–35.
6. Pasricha PJ.Unraveling the mystery of pain in chronic pancreatitis. Nat Rev Gastroenterol Hepatol. 2012;9(3):140–51.
7. Chinnakotla S, Bellin MD, Schwarzenberg SJ, Radosevich DM, Cook M, Dunn TB, etal. Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indi­cation, surgical techniques, postoperative management, and long-term outcomes. Ann Surg. 2014;260(1):56–64.
8. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J, etal. Hereditary pancreatitis and the risk of pancreatic cancer. International hereditary pancreatitis study group. J Natl Cancer Inst. 1997;89(6):442–6.
10 Total Pancreatectomy withIslet Cell Autotransplantation
9. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, etal. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226–37.
10. Nathan JD, Yang Y, Eaton A, Witkowski P, Wijkstrom M, Walsh M, etal. Surgical approach and short-term outcomes in adults and children undergoing total pancreatectomy with islet auto­transplantation: a report from the prospective observational study of TPIAT. Pancreatology. 2022;22(1):1–8.
11. Sutherland DER, Radosevich DM, Bellin MD, Hering BJ, Beilman GJ, Dunn TB, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg. 2012;214(4):409–24.
12. Conwell DL, Vargo JJ, Zuccaro G, Dews TE, Mekhail N, Scheman J, etal. Role of differential neuroaxial blockade in the evaluation and management of pain in chronic pancreatitis. Am J Gastroenterol. 2001;96(2):431–6.
13. Bahuva R, Walsh RM, Kapural L, Stevens T.Morphologic abnormalities are poorly predictive of visceral pain in chronic pancreatitis. Pancreas. 2013;42(1):6–10.
14. Dasgupta A.Chapter 4—Alcohol biomarkers: an overview. In: Dasgupta A, editor. Alcohol and its biomarkers. San Diego, CA: Elsevier; 2015. p.91–120. (Clinical Aspects and Laboratory Determination) https://www.sciencedirect.com/science/article/pii/B9780128003398000043.
15. Morgan KA, Lancaster WP, Owczarski SM, Wang H, Borckardt J, Adams DB.Patient selec­tion for total pancreatectomy with islet autotransplantation in the surgical management of chronic pancreatitis. J Am Coll Surg. 2018;226(4):446–51.
16. Naples R, Walsh RM, Thomas JD, Perlmutter B, McMichael J, Augustin T, etal. Short- and long-term surgical outcomes of total pancreatectomy with islet autotransplantation: a compar­ative analysis of surgical technique and intraoperative heparin dosing to optimize outcomes. Pancreatology. 2021;21(1):291–8.
17. Johnston PC, Lin YK, Walsh RM, Bottino R, Stevens TK, Trucco M, etal. Factors associ­ated with islet yield and insulin independence after total pancreatectomy and islet cell auto­transplantation in patients with chronic pancreatitis utilizing off-site islet isolation: Cleveland Clinic experience. J Clin Endocrinol Metab. 2015;100(5):1765–70.
18. Rickert C, Lei J, Markmann J.Islet autotransplantation for chronic pancreatitis. In: Current surgical therapy. 12th ed. Elsevier Health Sciences. 2016.
19. Naples R, Perlmutter BC, Thomas JD, McMichael J, Bottino R, Solomina J, etal. Clinical signicance of postoperative antibiotic treatment for positive islet cultures after total pancre­atectomy with islet autotransplantation. Pancreas. 2021;50(7):1000–6.
20. Naziruddin B, Iwahashi S, Kanak MA, Takita M, Itoh T, Levy MF.Evidence for instant blood­mediated inammatory reaction in clinical autologous islet transplantation. Am J Transplant. 2014;14(2):428–37.
21. Fackche N, Walsh CM, Singh VK, Makary MA.Total pancreatectomy with islet autotrans­plantation. In: Current surgical therapy. 13th ed. Elsevier Health Sciences; 2020.
22. Edil BH, Cooper MA, Makary MA. Laparoscopic pancreaticojejunostomy using a barbed suture: a novel technique. J Laparoendosc Adv Surg Tech. 2014;24(12):887–91.
23. Marquez S, Marquez TT, Ikramuddin S, Kandaswamy R, Antanavicius G, Freeman ML, etal. Laparoscopic and da Vinci robot-assisted total pancreaticoduodenectomy and intraportal islet autotransplantation: case report of a denitive minimally invasive treatment of chronic pancre­atitis. Pancreas. 2010;39(7):1109–11.
24. Galvani CA, Rilo HR, Samamé J, Porubsky M, Rana A, Gruessner RWG. Fully robotic­assisted technique for total pancreatectomy with an autologous islet transplant in chronic pan­creatitis patients: results of a rst series. J Am Coll Surg. 2014;218(3):e73.
25. Zureikat AH, Nguyen T, Boone BA, Wijkstrom M, Hogg ME, Humar A, etal. Robotic total pancreatectomy with or without autologous islet cell transplantation: replication of an open technique through a minimal access approach. Surg Endosc. 2015;29(1):176–83.
169
170
26. Gołębiewska JE, etal. Assessment of simple indices based on a single fasting blood sample as a tool to estimate beta-cell function after total pancreatectomy with islet autotransplantation— a prospective study. Transpl Int. 2019;32(3):280–90. https://doi.org/10.1111/tri.13364.
27. Wilson GC, Sutton JM, Abbott DE, Smith MT, Lowy AM, Matthews JB, etal. Long-term out­comes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? Ann Surg. 2014;260(4):659–67.
28. Fan CJ, Hirose K, Walsh CM, Quartuccio M, Desai NM, Singh VK, etal. Laparoscopic total pancreatectomy with islet autotransplantation and intraoperative islet separation as a treatment for patients with chronic pancreatitis. JAMA Surg. 2017;152(6):550–6.
29. Chung WS, Lin CL.Comorbid risks of deep vein thrombosis and pulmonary thromboem­bolism in patients with chronic pancreatitis: a nationwide cohort study. J Thromb Haemost. 2016;14(1):98–104.
30. Robbins AJ, Skube ME, Bellin MD, Dunn TB, Chapman SA, Berry KL, etal. Portal vein thrombosis after total pancreatectomy and islet autotransplant: prophylaxis and graft impact. Pancreas. 2019;48(10):1329–33.
31. Ahmad SA, Lowy AM, Wray CJ, D’Alessio D, Choe KA, James LE, etal. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg. 2005;201(5):680–7.
32. Webb MA, Illouz SC, Pollard CA, Gregory R, Mayberry JF, Tordoff SG, etal. Islet auto trans­plantation following total pancreatectomy: a long-term assessment of graft function. Pancreas. 2008;37(3):282–7.
33. Chinnakotla S, Radosevich DM, Dunn TB, Bellin MD, Freeman ML, Schwarzenberg SJ, etal. Long term outcomes of total pancreatectomy and islet auto transplantation for hereditary/ genetic pancreatitis. J Am Coll Surg. 2014;218(4):530–43.
34. Bellin MD, Beilman GJ, Sutherland DE, Ali H, Petersen A, Mongin S, etal. How durable is total pancreatectomy and intraportal islet cell transplantation for treatment of chronic pancre­atitis? J Am Coll Surg. 2019;228(4):329–39.
35. Barshes NR, Wyllie S, Goss JA.Inammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587–97.
36. Baldwin XL, Williams BM, Schrope B, Desai CS.What is new with total pancreatectomy and autologous islet cell transplantation? Review of current progress in the eld. J Clin Med. 2021;10(10):2123.
37. Walsh RM, Saavedra JRA, Lentz G, Guerron AD, Scheman J, Stevens T, etal. Improved qual­ity of life following total pancreatectomy and auto-islet transplantation for chronic pancreati­tis. J Gastrointest Surg. 2012;16(8):1469–77.
38. Dorlon M, Owczarski S, Wang H, Adams D, Morgan K.Increase in postoperative insulin requirements does not lead to decreased quality of life after total pancreatectomy with islet cell autotransplantation for chronic pancreatitis. Am Surg. 2013;79(7):676–80.
J. Chang et al.